EQS-Adhoc: Marinomed Biotech AG: Binding Term Sheet for the intended issuance of a convertible bond to the European Investment Bank (EIB) signed
|
EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action Korneuburg, Austria, 27. November 2024 - Marinomed Biotech AG (the “Company”) announces that it has signed a binding term sheet with the European Investment Bank (EIB) for the intended issuance of a convertible bond (registered bond in the name or order) with a nominal value of EUR 423,840, which is to be subscribed exclusively by the European Investment Bank (EIB) (excluding the statutory subscription rights of existing shareholders) against the contribution of a right of segregation. The convertible bond will evidence a conversion right in initially up to 84,768 shares of the Company at a conversion price of EUR 5 per share and will be issued in December 2024. In the event of conversion of the convertible bond, it is intended to issue the shares available from the conditional capital of the Company. A corresponding report on the planned exclusion of the statutory subscription rights of existing shareholders to convertible bonds will be published shortly. The required resolution of the Supervisory Board on the issuance of the convertible bond with the exclusion of subscription rights can be adopted at the earliest two weeks after publication of the report. The necessary consent of the insolvency administrator for the issuance of the convertible bond has not yet been obtained.
+++ End of ad-hoc announcement +++ End of Inside Information
27-Nov-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com |
| Language: | English |
| Company: | Marinomed Biotech AG |
| Hovengasse 25 | |
| 2100 Korneuburg | |
| Austria | |
| Phone: | +43 2262 90300 |
| E-mail: | office@marinomed.com |
| Internet: | www.marinomed.com |
| ISIN: | ATMARINOMED6 |
| WKN: | A2N9MM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market) |
| EQS News ID: | 2039579 |
| End of Announcement | EQS News Service |
|
|
2039579 27-Nov-2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 4,67 | 6,14 | 8,12 | 11,63 | 11,28 | 9,18 | 0,00 | |
| EBITDA1,2 | -4,90 | -5,88 | -5,39 | -3,54 | -4,24 | -4,45 | 0,00 | |
| EBITDA-Margin3 | -104,93 | -95,77 | -66,38 | -30,44 | -37,59 | -48,48 | 0,00 | |
| EBIT1,4 | -5,14 | -6,21 | -5,82 | -4,14 | -4,91 | -5,13 | 0,00 | |
| EBIT-Margin5 | -110,06 | -101,14 | -71,68 | -35,60 | -43,53 | -55,88 | 0,00 | |
| Net Profit (Loss)1 | -12,10 | -7,22 | -6,01 | -5,89 | -6,40 | -6,80 | 0,00 | |
| Net-Margin6 | -259,10 | -117,59 | -74,02 | -50,65 | -56,74 | -74,07 | 0,00 | |
| Cashflow1,7 | -4,32 | -7,64 | -6,89 | -4,87 | -5,20 | -4,53 | 0,00 | |
| Earnings per share8 | -12,10 | -5,10 | -4,10 | -4,00 | -4,30 | -4,50 | -2,40 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: BDO
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Marinomed Biotech | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A2N9MM | ATMARINOMED6 | AG | 25,43 Mio € | 01.02.2019 | Halten | 8FWR88QM+8R |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -7,15 | 0,00 | 0,00 | -3,15 | -2,51 | -5,62 | 2,77 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 20.06.2024 | 22.05.2024 | 20.08.2024 | 21.11.2024 | 16.04.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +45,10% | +19,90% | -52,17% | -53,72% | -80,93% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
